Key facts
- Ascend (Drug Discovery)’s last known valuation is $150.9M.
- It has raised $194.3M; the latest was Early Stage VC ($42.5M) in Nov 2024.
- Notable investors include DCVC, Cathay Capital, Digitalis Ventures, Deerfield Management, DCVC Bio — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Ascend (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for Ascend (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ascend (Drug Discovery)
Developer of a biotechnology platform designed to support the development and commercialization of advanced therapies. The company provides process development, manufacturing, and regulatory expertise from research to clinical and commercial scale, enabling biotechnology teams to integrate scalable manufacturing into their operations from the beginning.
- Sector
- Healthcare
- HQ
- Rockville, MD, United States
- Founded
- 2021
- Employees
- 128
- Website
- ascend-adv.com/
- Ownership
- Privately Held (backing)
Ascend (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ascend (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ascend (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.